Literature DB >> 28721047

The role of microglia in multiple sclerosis.

Chun Luo1, Chongdong Jian1, Yuhan Liao1, Qi Huang1, Yuejuan Wu1, Xixia Liu1, Donghua Zou2, Yuan Wu1.   

Abstract

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS). Microglia are the resident innate immune cells in the CNS; they play an important role in the processes of demyelination and remyelination in MS. Microglia can function as antigen-presenting cells and phagocytes. In the past, microglia were considered to be the same cell type as macrophages, and researchers have different opinions about the role of microglia in MS. This review focuses on the original classification of microglia and their role in the pathogenesis of MS. Moreover, we present a hypothetical model for the role of microglia in the pathogenesis of MS based on recent findings.

Entities:  

Keywords:  macrophage; microglia; multiple sclerosis; myelin

Year:  2017        PMID: 28721047      PMCID: PMC5499932          DOI: 10.2147/NDT.S140634

Source DB:  PubMed          Journal:  Neuropsychiatr Dis Treat        ISSN: 1176-6328            Impact factor:   2.570


Introduction

Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system (CNS) characterized by focal lesions of inflammation, axonal loss, gliosis, and demyelination that affect the white and gray matter.1,2 In MS patients, destruction of myelin in the CNS is associated with activated macrophages or microglia,2–4 which are thought to be involved in the disease pathogenesis.5 Microglia are the resident innate immune cells of the CNS and play an important role in inflammatory and immune responses.6 Microglia express major histocompatibility (MHC) antigens I and II and secrete many proinflammatory and anti-inflammatory cytokines such as interleukin-1 (IL-1), tumor necrosis factor-α (TNF-α), and IL-10, as well as costimulatory molecules such as intercellular adhesion molecule-1 (ICAM-1), B7-1, and B7-2. Microglia also express Fc receptors (I–III) and complement receptors (CR1, CR2, and CR4).5,7 On one hand, microglia promote remyelination through the expression of anti-inflammatory molecules, phagocytosis of debris, and repair of tissues. On the other hand, microglia present antigens and secrete proinflammatory molecules that can damage the myelin sheath and/or oligodendrocytes.8 As antigen-presenting cells (APCs), microglia are involved in cross-talk with other immune cells, and such cross-talk leads to the activation of T cells during the course of demyelination and remyelination in MS.7,9

Origins of microglia

Activated microglia express many of the same cell surface markers as infiltrating monocyte-derived macrophages. It is also very difficult to distinguish these cell types because they are similar in morphology. In addition, they have many functional similarities, such as presentation of antigens and production of cytokines, oxidative radicals, chemokines, and NO. Because of the similarities in morphology and function, many researchers have referred to these cells collectively as macrophages/microglia. In addition, microglia and macrophages were originally thought to have originated from the same myeloid precursor and lineage in the bone marrow.10 However, recent reports showed that bone marrow-derived macrophages are very different from microglia. In fact, these two cell types are derived from distinct myeloid populations.11–13 On the basis of the serial block-face scanning electron microscopy, Yamasaki et al found that monocyte-derived macrophages are associated with nodes of Ranvier and initiated demyelination, whereas microglia clear debris in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS.14 In the embryonic yolk sac, the erythromyeloid precursors migrate to the developing neural tube, and then differentiate into microglia.12,13 By contrast, macrophages are derived from the hematopoietic stem cells of the bone marrow, which differentiate into monocytes that circulate throughout the body, with the exception of the brain and spine parenchyma.

Subgroups of microglia

Activated microglia can be divided into M1 and M2 subgroups.15 M1 microglia promote inflammation and oligodendrocyte damage, whereas M2 microglia regulate immune functions and promote repair in inflammatory diseases of the CNS.16 M1 microglia produce proinflammatory cytokines such as IL-1β and TNF-α and induce NO synthase activity. In vitro, adult human M1 microglia express CD86, CD16/32, CD40, CD74, and CCR7 on their surfaces. In contrast, M2 microglia secrete anti-inflammatory cytokines, such as IL-10, and express CD206 (mannose receptor), the anti-inflammatory cytokine CCL22, and Arg1 (arginase).17 Some researchers found that microglia can differentiate into many subgroups with various functions upon different types of stimulation. Activation was shown to be strongly affected by the environment, which resulted in different activation states characterized by the production of different kinds of mediators and expression of various cell surface markers.18–22 Erny et al found that the function of microglia changed with the host microbiota.23 In addition, Xue et al found that activated microglia can be classified into at least nine subgroups based on a transcriptomic signature, which demonstrates the complexity and diversity of microglia.24 Using the EAE mouse model of demyelination, Olah et al found that microglia have different morphologies during demyelination and remyelination.25 Miron et al also observed plasticity in microglia during different phases of EAE where M2 microglia regulated the responses of oligodendrocyte progenitor cells (OPCs).26 In addition, changes in the morphology of microglia were accompanied by changes in function; during the course of remyelination, microglia phagocytosed apoptotic cells and myelin debris.26 These studies have revealed the plasticity of microglia and the diversity of microglial function under different conditions.

Microglia in the pathogenesis of MS

Microglia have various immunologic and neurobiologic functions that are closely associated with chronic inflammatory diseases, such as MS. The hallmark of MS pathology is demyelinated plaques in the white and gray matter with preservation of axons.27 A systematic study of brain biopsies showed that subcortical and cortical demyelination was present in patients in the early stages of MS.28 In the cuprizone-induced demyelination EAE model, activated microglia were found in lesions of the CNS and were thought to contribute to the CNS inflammation in MS.29,30 Besides the physical presence of microglia at sites of demyelination, the role of microglia in the pathogenesis of MS is only beginning to be revealed.

Microglia and oxidative damage

Several studies have suggested that oxidative injury plays an important role in the pathogenesis of demyelinating diseases, such as MS and Alzheimer’s disease. Extensive loss and apoptosis of mature oligodendrocytes were found in MS lesions,31 and oxidized DNA and lipids are present in oligodendrocytes and the myelin of active MS lesions.32,33 OPCs are particularly vulnerable to oxidative stress because they have lower levels of antioxidant enzymes and antiapoptotic proteins and higher levels of proapoptotic proteins.34,35 The oxidative burst in activated microglia and macrophages is regarded as the major source of reactive oxygen species (ROS) in MS.36 The extent of lipid and DNA oxidation correlated significantly with inflammation and oxidative injury of oligodendrocytes and neurons, which was also associated with active demyelination and axonal and neuronal injury in MS.37 Furthermore, van Horssen et al found extensive oxidative injury and upregulated expression of oxidative molecules and antioxidant enzymes in MS lesions.38–40 Other recent data also showed that activated microglia produce ROS and NO radicals in MS lesions, which suggested their role in the demyelination and neurodegeneration process of MS.41–45 These findings indicate that activated microglia are an important source of oxidative damage: activated microglia promote oxidative stress in MS, which accounts for the features of MS pathological findings.46 Ablation of microglia protected the gray and white matter in EAE mice.47 Microglial Hv1 proton channels promoted cuprizone-induced demyelination through ROS production. Liu et al found that Hv1−/− mice had reduced microglial accumulation, increased OPC proliferation, ROS production, and partial protection from demyelination and motor deficits after cuprizone exposure.48

Microglia in remyelination

Remyelination is the process of myelin regeneration occurring simultaneously with or following demyelination, which is characterized by the appearance of myelin around the axon. Clearance of debris and proliferation of oligodendrocytes are key processes in remyelination, followed by recruitment and proliferation of OPCs, which differentiate into mature myelinating oligodendrocytes.49 However, we observed that remyelination failed in the majority of MS patients, who became progressively disabled. The extent of remyelination was partly related to the location of the lesion; remyelination was found more frequently in lesions of the cortical or subcortical white matter than in periventricular areas.50 Lampron et al found that CX3CR1 knockout mice had reduced myelin debris clearance and impaired remyelination due to the ineffective function of microglia/macrophages.51 The phagocytosis of myelin debris by microglia and macrophages plays an important role in the initiation of remyelination.52 The reaction of macrophages to demyelination affects the local microenvironment and subsequently impacts the efficiency of remyelination.53 Due to a block in the differentiation of OPCs, remyelination usually fails in chronic MS.54 Kuhlmann et al found that microglia produced TNF-α, IGF-1, and FGF-2, which were very important for the proliferation of oligodendrocytes.55 IL-4 injection increased oligodendrocyte proliferation in the spinal cord of EAE mice, which suggested the potential involvement of microglia/macrophages in remyelination.56 Miron et al found that oligodendrocyte differentiation in cerebellar slices was improved in vitro by culture in M2 microglia-conditioned medium and decreased in vivo after depletion of M2 microglia; blocking of activin A secreted by M2 microglia suppressed oligodendrocyte differentiation during remyelination.57 The functions of microglia/macrophages in demyelination and remyelination are summarized in Table 1.
Table 1

Summary of the function of microglia/macrophage in demyelination and remyelination

Experimental modelMicroglia/macrophage functionReferences
Cuprizone-induced demyelinationMicroglial hv1 proton channel promoted demyelination through oxidative damageLiu et al48
Cerebellar culture stimulated with endotoxinRelease of proinflammatory cytokines (IL-1β, IL-6, TNF-α) and increased expression of iNOS and ROSdi Penta et al58
Cuprizone-induced demyelination and remyelinationMicroglia contributed to the repair-permissive environment by providing growth factors IGF-1 and FGF-2Voss et al9
Cuprizone-induced demyelinationCX3CR1 knockout mice had insufficient myelin debris clearance and impaired remyelinationLampron et al51
Cerebellar slice culturesBlockade of M2 cell-derived activin A inhibited oligodendrocyte differentiation during remyelinationMiron et al26

Abbreviations: IL-1β, interleukin-1β; ROS, reactive oxygen species; TNF-α, tumor necrosis factor-α.

Microglia interactions with T cells

T cells play an important role in the pathogenesis of MS. Although the etiology of inflammation is still unclear, it has been found that T cells, specifically Th1 and Th17 cells, have an important link to MS pathology.59,60 In MS patients and animal models, infiltrating T cells and activated microglia are found in the CNS lesions. Microglia play a key role in recruitment of adaptive immune cells to the CNS.61 Activated microglia act as APCs through the expression of class I and II MHCs simultaneously with costimulatory molecules,62 through which T cells can recognize activated microglia. The microglia can interact with CD28 or cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) on T cells. The costimulatory molecules B7-1 and B7-2 expressed by microglia bind CD28 to positively stimulate the T cell to proliferate, differentiate, and secrete cytokines. Conversely, binding to CTLA4 causes T-cell anergy or apoptosis.63 The costimulatory molecule CD40 on microglia is also a key factor in T-cell activation. A study of mouse bone marrow chimeras found that CD40 knockout significantly abrogated T-cell activation in the CNS. Different kinds of T cells have different effects on microglia through cell-to-cell contact. Myelin basic protein (MBP)-primed Th1 cells (isolated from MBP-immunized mice) induced the expression of the proinflammatory molecules NO, IL-1, and TNF-α in mouse primary microglia and astroglia.64 MBP-primed Th2 cells, however, induced the production of brain-derived neurotrophic factor and neurotrophin-3.64 Ebner et al found that microglia, as inducible APCs, induced proliferation of Tregs and, therefore, promoted the balance between beneficial and inflammatory T-cell responses in EAE.65 Bsibsi et al found that IFN-γ, released by infiltrating T cells, along with heat shock protein (HSP)B5 changed the protective response of microglia into a robust proinflammatory response as shown by the release of TNF-α, IL-6, IL-12, IL-1β, and ROS.66 Oligodendrocytes are a pivotal local source of HSPB5 in MS-affected brains.66 The interaction between T cells and microglia likely affects many aspects of MS pathobiology. Under different conditions, T-cell interaction with microglia may generate different outcomes.

Hypothetical model of the pathogenesis of MS

In the quest to understand the pathogenesis of MS, many studies have focused on the T cell and have provided much insight. In particular, Th1 and Th17 cells have been considered central players in MS pathology. It has been widely accepted that the disease process is initiated by the adaptive immune response, then infiltration of activated T cells into the CNS with associated upregulation of proinflammatory mediators activate local microglia/macrophages, leading to inflammation and demyelination.67,68 This hypothesis considers T-cell-dependent and microglia/macrophage-mediated inflammation as central to this autoimmune disease.69,70 However, some researchers have also found that oligodendrocyte apoptosis in MS lesions or damage is not associated with T cells or peripheral macrophages.71–74 Insufficiency or the absence of lymphocyte recruitment after the initial relapsing phase of the disease indicates that other factors drive pathology in late-stage disease. There is increasing evidence of plasma cell and innate immunity involvement in progressive disease.75 These findings challenge the old theory. In recent years, the contribution of innate immune cells to the pathogenesis of MS has been appreciated.76 Microglia comprise 10%–20% of glial cells and are the most common immune cells in the CNS.77,78 Microglia are considered resident macrophages of the CNS that express all known toll-like receptors (1–9).79 They are involved in phagocytosis, antigen presentation, and production of cytokines.60 Therefore, we postulate that the immune reaction initiates in the CNS and immune cells (including T cells/B cell) infiltrate into the CNS as a result. An unknown causative agent sets off a local inflammatory reaction, after which activated microglia are stimulated by the microenvironment to differentiate into many subgroups that then serve as APCs, phagocytes, and immune effector cells to activate T cells. Activated T cells can then cross the blood–brain barrier and result in a peripheral immune response. Subsequently, activated T cells, B cells, and macrophages migrate from the periphery into the CNS, which exacerbates the inflammation or leads to relapse. This hypothesis could explain some phenomena in MS patients. First, the APCs (microglia and macrophages) originate in the CNS, are recognized by CNS-resident cells, and remain localized within the CNS, which could explain why MS patients experience no peripheral complications, such as autoimmune nephritis and arthritis. Second, the inflammatory cascade occurs entirely within the CNS, which could explain the insufficiency or the absence of lymphocyte recruitment into the CNS after the initial relapsing phase of MS (Figure 1).71
Figure 1

Hypothetical model for the role of microglia in MS.

Abbreviations: APC, antigen-presenting cell; BBB, blood–brain barrier; MS, multiple sclerosis.

Conclusion

There are likely more subgroups of microglia than presently known; therefore, determining the phenotypes and functions of each subgroup will be crucial for understanding the role of microglia in MS. We suggest the importance of defining macrophages80 according to their stimulation under experimental conditions and phenotype based on a combination of cell surface markers; this also could be an informative approach for microglia. A better understanding of the diversity of roles of microglia during inflammation and regeneration in the CNS will contribute to establishing new therapeutic strategies for MS patients.
  75 in total

1.  Immunopathology of secondary-progressive multiple sclerosis.

Authors:  J W Prineas; E E Kwon; E S Cho; L R Sharer; M H Barnett; E L Oleszak; B Hoffman; B P Morgan
Journal:  Ann Neurol       Date:  2001-11       Impact factor: 10.422

2.  Identification of a microglia phenotype supportive of remyelination.

Authors:  Marta Olah; Sandra Amor; Nieske Brouwer; Jonathan Vinet; Bart Eggen; Knut Biber; Hendrikus W G M Boddeke
Journal:  Glia       Date:  2011-11-09       Impact factor: 7.452

3.  Characterisation of microglia during de- and remyelination: can they create a repair promoting environment?

Authors:  Elke Verena Voss; Jelena Škuljec; Viktoria Gudi; Thomas Skripuletz; Refik Pul; Corinna Trebst; Martin Stangel
Journal:  Neurobiol Dis       Date:  2011-09-21       Impact factor: 5.996

Review 4.  Multiple sclerosis--the plaque and its pathogenesis.

Authors:  Elliot M Frohman; Michael K Racke; Cedric S Raine
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

5.  Microglial activation milieu controls regulatory T cell responses.

Authors:  Friederike Ebner; Christine Brandt; Peggy Thiele; Daniel Richter; Ulrike Schliesser; Volker Siffrin; Jutta Schueler; Tobias Stubbe; Agnes Ellinghaus; Christian Meisel; Birgit Sawitzki; Robert Nitsch
Journal:  J Immunol       Date:  2013-10-21       Impact factor: 5.422

6.  Early cellular events in multiple sclerosis. Intimations of an extrinsic myelinolytic antigen.

Authors:  Frederick W Gay
Journal:  Clin Neurol Neurosurg       Date:  2005-12-20       Impact factor: 1.876

Review 7.  Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis.

Authors:  E N Benveniste
Journal:  J Mol Med (Berl)       Date:  1997-03       Impact factor: 4.599

8.  Microglial cell activation and proliferation precedes the onset of CNS autoimmunity.

Authors:  Eugene D Ponomarev; Leah P Shriver; Katarzyna Maresz; Bonnie N Dittel
Journal:  J Neurosci Res       Date:  2005-08-01       Impact factor: 4.164

9.  Oxidative damage in multiple sclerosis lesions.

Authors:  Lukas Haider; Marie T Fischer; Josa M Frischer; Jan Bauer; Romana Höftberger; Gergö Botond; Harald Esterbauer; Christoph J Binder; Joseph L Witztum; Hans Lassmann
Journal:  Brain       Date:  2011-06-07       Impact factor: 13.501

Review 10.  Demyelination: the role of reactive oxygen and nitrogen species.

Authors:  K J Smith; R Kapoor; P A Felts
Journal:  Brain Pathol       Date:  1999-01       Impact factor: 6.508

View more
  56 in total

Review 1.  Microglial interactions with the neurovascular system in physiology and pathology.

Authors:  Xiaoliang Zhao; Ukpong B Eyo; Madhuvika Murugan; Long-Jun Wu
Journal:  Dev Neurobiol       Date:  2018-02-01       Impact factor: 3.964

2.  Human retrovirus pHEV-W envelope protein and the pathogenesis of multiple sclerosis.

Authors:  Robert P Lisak
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-09       Impact factor: 11.205

3.  Intraganglionic macrophages: a new population of cells in the enteric ganglia.

Authors:  David Dora; Emily Arciero; Ryo Hotta; Csilla Barad; Sukhada Bhave; Tamas Kovacs; Adam Balic; Allan M Goldstein; Nandor Nagy
Journal:  J Anat       Date:  2018-07-18       Impact factor: 2.610

4.  Beneficial Effects of the Calcium Channel Blocker CTK 01512-2 in a Mouse Model of Multiple Sclerosis.

Authors:  Rodrigo B M Silva; Samuel Greggio; Gianina T Venturin; Jaderson C da Costa; Marcus V Gomez; Maria M Campos
Journal:  Mol Neurobiol       Date:  2018-04-17       Impact factor: 5.590

5.  Microglia polarization by methylprednizolone acetate accelerates cuprizone induced demyelination.

Authors:  Golaleh Noorzehi; Parichehr Pasbakhsh; Maryam Borhani-Haghighi; Iraj Ragerdi Kashani; Soheila Madadi; Fatemeh Tahmasebi; Saied Nekoonam; Maryam Azizi
Journal:  J Mol Histol       Date:  2018-08-24       Impact factor: 2.611

6.  Discovery of novel L-type voltage-gated calcium channel blockers and application for the prevention of inflammation and angiogenesis.

Authors:  Madhu Sudhana Saddala; Anton Lennikov; Anthony Mukwaya; Yan Yang; Michael A Hill; Neil Lagali; Hu Huang
Journal:  J Neuroinflammation       Date:  2020-04-25       Impact factor: 8.322

7.  Adoptive transfer of immunomodulatory M2 macrophages suppresses experimental autoimmune encephalomyelitis in C57BL/6 mice via blockading NF-κB pathway.

Authors:  F Chu; M Shi; Y Lang; Z Chao; T Jin; L Cui; J Zhu
Journal:  Clin Exp Immunol       Date:  2021-02-01       Impact factor: 4.330

8.  Clinical characteristics of a large multi-center cohort of people with multiple sclerosis over age 60.

Authors:  Le H Hua; Carrie M Hersh; Fan Tian; Ellen M Mowry; Kathryn C Fitzgerald
Journal:  Mult Scler Relat Disord       Date:  2020-11-23       Impact factor: 4.339

9.  Metformin Therapy Attenuates Pro-inflammatory Microglia by Inhibiting NF-κB in Cuprizone Demyelinating Mouse Model of Multiple Sclerosis.

Authors:  Mahdad Abdi; Parichehr Pasbakhsh; Maryam Shabani; Saied Nekoonam; Asie Sadeghi; Fardin Fathi; Morteza Abouzaripour; Wael Mohamed; Kazem Zibara; Iraj Ragerdi Kashani; Adib Zendedel
Journal:  Neurotox Res       Date:  2021-09-27       Impact factor: 3.911

Review 10.  Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases.

Authors:  Falguni Baidya; Mariya Bohra; Aishika Datta; Deepaneeta Sarmah; Birva Shah; Priya Jagtap; Swapnil Raut; Ankan Sarkar; Upasna Singh; Kiran Kalia; Anupom Borah; Xin Wang; Kunjan R Dave; Dileep R Yavagal; Pallab Bhattacharya
Journal:  Immunology       Date:  2020-10-06       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.